China’s Tot Biopharm Secures First Antibody Approval With Avastin Biosimilar

Regulator NMPA Approves Pusintin Biosimilar Product For Cancer Indications

 
• By Dean Rudge

After listing on the Hong Kong stock exchange in late 2019, China’s Tot Biopharm has delivered its first antibody drug approval, with its Pusintin (bevacizumab) biosimilar to Avastin.

China - Suzhou City
Tot has manufacturing in the Suzhou Industrial Park • Source: Shutterstock

More from Biosimilars

More from Products